precision medicine

Viewing posts tagged precision medicine

11 Sep 2017

Nano Drills Destroy Cancer Cells

By Jay Goth

Researchers have long sought alternative treatments capable of killing cancer cells while leaving healthy cells alone. Now, a team of scientists from Rice, Durham, and North Carolina State Universities may have uncovered one: A new innovation uses light to activate microscopic “nanomachines” that can drill into individual cancer cells.

In one test, it took just 60 seconds for a nanomachine to pierce the outer shell of a prostate cancer cell with dozens of tiny holes; overall, it took 1-3 minutes to destroy the cell by necrosis.

“Once developed, this approach could provide a potential step change in non-invasive cancer treatment and greatly improve survival rates and patient welfare globally.”

– Dr. Robert Pal of Durham University
Check out the entire article at CB Insights.

CB Insights

03 Jul 2017

Precision Medicine Beyond the Genome

By Jay Goth

Today, doctors can tailor a drug therapy to your unique genetic profile, giving you the full benefits of a drug while reducing unwanted side effects — all in harmony with the blueprints of your biology.

Now, through a new $30,000 grant from the J.R. & Inez Jay Fund, researchers at the University of Kansas and Children’s Mercy Hospital in Kansas City are investigating how to tailor drug therapies using exosomes — nanoscale sacs full of biomarkers like lipids, proteins and nucleic acids found in bodily fluids — that can be used to achieve a noninvasive “liquid biopsy.”

“Beyond genetics, there are layers of complexities during development from childhood to adolescence to adulthood.”

–Michael Wang, University of Kansas

The new exosome-based technology could be especially useful in developing personalized medical treatments for children and teens, Wang said.

For the full story visit the University of Kansas website here.

Visit the University of Kansas

30 Jun 2017

Surfing with DAVE

By Jay Goth

The growth in cancer genomics has been one of the most exciting scientific and technological developments in cancer research, spurring significant advances in patient care and laying the groundwork for many future advances.

In the year since it was launched, the National Cancer Institute’s Genomic Data Commons (GDC) has collected and harmonized a vast quantity of cancer genomics data—more than 4.5 petabytes—which has been fundamental in the recent progress against cancer and holds the promise for continued improvement in our ability to diagnose, treat, and care for patients.

Now, as a data-analysis system, the GDC is taking major steps toward engaging the broader research community and encouraging further collaboration and data sharing. They recently introduced a new program – Data Analysis, Visualization, and Exploration Tools, an online, open-access cancer research resource called DAVE.

DAVE is a new web interface for exploring and analyzing cancer genomic data, in real time, online, without the need to download or process the data.

DAVE provides an unprecedented level of flexibility in exploring the data. Researchers can create custom cohorts for analysis by selecting patients with particular altered genes or other relevant biological and clinical features. And researchers are no longer bound to analyzing patients only in the context of their original project cohorts—a powerful innovation given the recent evidence that a tumor’s molecular features are far more accurate and informative for cancer subtyping than tissue of origin or histology.

Another step forward for precision medicine! For the details, visit the National Cancer Institute.

29 Jun 2017

Finding the Source of Cancers

By Jay Goth

Investigators at the University of California San Diego School of Medicine and at Xijing Hospital and Sun Yat-sen Cancer Center in China say that DNA methylation can provide effective markers for at least four major cancers.

The biomarkers are able to differentiate malignant tissues from normal tissues and also provide information on prognosis and survival, according to the researchers.

“This new simple method will be of great value to pinpoint the primary source of the tumor.”

–Michael Karin, Ph.D., Professor of Pharmacology, UC San Diego School of Medicine.

“Choosing the proper cancer treatment with the best chance of recovery and survival depends greatly upon accurately diagnosing the specific type or subtype of cancer,” said Kang Zhang, M.D., Ph.D., founding director of the Institute for Genomic Medicine and co-director of biomaterials and tissue engineering at the Institute of Engineering in Medicine, both at UC San Diego School of Medicine.

Read the entire article at Genetic Engineering and Biotechnology News here.

22 Jun 2017

NGS Companion Diagnostic Approved by FDA

By Jay Goth

The US Food and Drug Administration today approved the first next-generation sequencing-based companion diagnostic that can analyze alterations in a panel of genes predictive of response across three non-small cell lung cancer treatments.

The panel, however, gauges alterations in 23 genes in total. The test report will not only indicate whether patients have ROS1, EGFR, and BRAF alterations linked to the three FDA-approved treatments, but also the presence or absence of variants in other genes.

This initial approval makes way for Thermo Fisher to quickly expand the indication of the panel into new markers predictive of drug response. The company is actively working with other drugmakers to expand the indications for the Oncomine Dx Target Test.

Read the entire article at Genome Web.

genomeweb logo

Get more genomic news at GenomeWeb

21 Jun 2017

Breakthrough FDA Ruling

By Jay Goth

The Food and Drug Administration (FDA) granted accelerated approval to the immunotherapy pembrolizumab for patients with solid tumors that have one of two specific genetic features known as mismatch repair deficiency and high microsatellite instability. The approval covers adult and pediatric patients whose cancer has progressed despite prior treatment and who have no alternative treatment options.

This is the first time that FDA has approved a cancer treatment based solely on the presence of a genetic feature in a tumor, rather than the patient’s cancer type.

“I think this is a step forward for precision medicine.”

–James Gulley, M.D., Ph.D., head of the immunotherapy section of NCI’s Center for Cancer Research

Having a biomarker to identify patients who are most likely to respond is “an area we have widely anticipated as being the next step in understanding how to better use immunotherapies,” said Dr. Gulley. “It’s a welcome first step, and there’s much more yet to be done.”

For the full article, visit the National Cancer Institute page here.

19 Jun 2017

Key to Metastasis?

By Jay Goth

A team at Johns Hopkins has discovered the biochemical mechanism that tells cancer cells to break off from the primary tumor and spread throughout the body, a process called metastasis. Some 90 percent of cancer deaths are caused when cancer metastasizes.

“…what we came up with through our studies was this drug cocktail that could potentially inhibit the spread of cancer.”

— Hasini Jayatilaka, post-doctoral fellow at Johns Hopkins

Typically, cancer research and treatment has focused on shrinking the primary tumor through chemotherapy or other methods. But, the team said, by attacking the deadly process of metastasis, more patients could survive.
Check out the whole article in the Baltimore Sun by clicking here.

14 Jun 2017

Institute for Protein Innovation Launched

By Jay Goth

The Institute for Protein Innovation will work to pursue new therapies for currently intractable diseases by bringing together leaders with backgrounds in academic research, the biopharma industry, and biomedical investing.

The Institute plans to curate information related to DNA sequence, protein expression, and functional validation of these reagents, including source code, in a publicly-accessible web portal, with the goal of accelerating the development of new drugs and supporting existing large-scale research efforts, citing the Human Cell Atlas.

The Institute said it will recruit researchers focused on directed evolution, cell-line development, and biophysical protein characterization, in addition to glycoprotein expression and antibody discovery expertise.

“Despite their pivotal importance in research and medicine, proteins lag behind DNA and RNA in institutional research support and funding.”

–Timothy A. Springer, Ph.D., Founder and Latham Family Professor at Harvard Medical School and Boston Children’s Hospital

Read the full article at Genetic Engineering and Biotechnology News here.

New Article in GEN

13 Jun 2017

Tissue Chips Matter!

By Jay Goth
tissue on a chip

Check this video from NCATS


How can we speed new drugs to market? One of the cool innovations coming to trials is the concept of “tissue on a chip”. Basically, scientists are mimicking human organs and testing drug compounds on these 3-D platforms. Check out this video for a quick explanation.

To find out more, go to the NCATS “Tissue on a Chip” website.

NCATS logo

National Center for Advancing Translational Sciences main website

12 Jun 2017

Precision Medicine’s All of Us Kicks Off

By Jay Goth

All of Us, the Precision Medicine Initiative that aims to revolutionize the path to improving health, has launched its beta phase.
The All of Us Research Program is a historic effort to gather data from one million or more people living in the United States to accelerate research and improve health. By taking into account individual differences in lifestyle, environment, and biology, researchers will uncover paths toward delivering precision medicine.
The program intends to get at least 1 million volunteers to sign up to contribute information on their genetic makeup, environmental factors, lifestyle choices, medical histories, and personal device and sensor data.

“By providing information about their health, lifestyles, and environments over the course of many decades, these volunteers will be important partners in helping create an unprecedented research resource to drive future discoveries.”

–Program Director Eric Dishman
The full announcement of the beta is available here.

Recent Comments
    More Posts